{"groups":[{"description":"All eligible patients will receive up to 2 cycles of CPX-351 for remission induction. The CPX-351 dose for the first induction cycle is 100 units/m\\^2 (corresponds to 44 mg/m\\^2 daunorubicin and 100 mg/m\\^2 cytarabine) on Days 1, 3 and 5. A second induction cycle at the same CPX-351 dose is administered on Days 1 and 3 for patients with CR/CRi but positive residual disease (MRD ≥0.1%) by flow cytometry. Patients attaining complete remission and MRD \\< 0.1% could proceed to hematopoietic stem cell transplantation (HSCT). If HSCT cannot be performed within four weeks from the evaluation date (Day 22 of the first cycle), patients will receive a second course with lower doses of daunorubicin (29 mg/m\\^2) and cytarabine (65 mg/m\\^2).","id":"FG000","title":"CPX-351 (Vyxeos)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"25"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"25"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"All 25 patients with Secondary Myeloid Neoplasms (SMN) were eligible for the study.","recruitmentDetails":"25 patients enrolled in St. Jude between 1/17/2023 and 7/24/2025."}